2 April, Inozyme Pharma CEO Douglas A. Treco sold 7,523 shares; Q1 earnings missed estimates by $0.04.
Inozyme Pharma CEO Douglas A. Treco sold 7,523 shares for $52,209.62 on 2nd Apr, leaving him with 20,665 shares valued at $143,415.10. The company's Q1 earnings missed estimates by $0.04. Their lead product, INZ-701, targets deficiencies and end-stage kidney disease. Major institutional investors have increased their stakes, and analysts reaffirm "buy" and "outperform" ratings with price targets of $16.00 and $15.00.
April 06, 2024
3 Articles